We propose to establish the Center for Hemoglobin Research in Minorities (CHaRM), which will build on and synergize with the existing HBCU Research Scientist Program. The CHaRM's ultimate goal is to provide and to improve the necessary research infrastructure, while augmenting science education and research training for pre- and postdoctoral students, and strengthening scientific faculty research and career development. We will establish a NHLBI Research Center at Howard University that will augment and strengthen research capabilities and resources in biomedical and behavioral research related to heart, lung and blood diseases and disorders in minority populations. This proposal will build on previously developed Research Scientist Program at Howard University's Center for Sickle Cell Disease (CSCD) that was supported by NHLBI from 1999 to 2012 and recently received the P30 award for Phase I of this program.
In Aim 1, we will establish a center of excellence for the study of hemoglobinopathies, iron metabolism, and oxygen sensing. We will recruit an external mid-level or senior investigator who will serve as program director and retain the existing recently hired junior faculty. We will also establish a steering committee, an external advisory board and use an external evaluator for the program.
In Aim 2, we will establish an administrative core to provide support and conduct training activities.
In Aim 3, we will educate and train minority students and fellows by providing research and laboratory experience, developing additional scientific curricula, facilitate scientific exchange and conduct seminars.
In Aim 4, we will expand and enhance the research advances made by the Howard University Research Scientist Program in clinical and molecular aspects of sickle cell disease, iron metabolism, and oxygen sensing.
In Aim 5, we will enhance and facilitate existing collaborations within and outside of Howard University and share existing resources. The underlying themes of the research we envision are to reduce health disparities and to enhance excellence in research into heart, lung and blood diseases at Howard University. In pursuit of the scientific and educational goals, an integral part of the program will be to obtain additional research support from NIH and other sources.

Public Health Relevance

The mission of the CHaRM is relevant to public Health because it is aimed at reducing health disparities and enhancing excellence into heart, lung and blood diseases at Howard University. The proposed activities are relevant to the NIH mission that pertains to reduce vulnerability of the population to chronic and infectious diseases and to train and educate minority students and medical fellows.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Specialized Center (P50)
Project #
1P50HL118006-01
Application #
8489410
Study Section
Special Emphasis Panel (ZHL1-CSR-B (F1))
Program Officer
Lee, Albert
Project Start
2013-08-22
Project End
2018-06-30
Budget Start
2013-08-22
Budget End
2014-06-30
Support Year
1
Fiscal Year
2013
Total Cost
$1,329,811
Indirect Cost
$471,217
Name
Howard University
Department
None
Type
Schools of Medicine
DUNS #
056282296
City
Washington
State
DC
Country
United States
Zip Code
20059
Ammosova, Tatyana; Platonov, Maxim; Ivanov, Andrei et al. (2014) 1E7-03, a low MW compound targeting host protein phosphatase-1, inhibits HIV-1 transcription. Br J Pharmacol 171:5059-75
Darbari, Deepika S; Nouraie, Mehdi; Taylor, James G et al. (2014) Alpha-thalassaemia and response to hydroxyurea in sickle cell anaemia. Eur J Haematol 92:341-5
Nekhai, Sergei; Petukhov, Michael; Breuer, Denitra (2014) Regulation of CDK9 activity by phosphorylation and dephosphorylation. Biomed Res Int 2014:964964
Kumari, Namita; Iordanskiy, Sergey; Kovalskyy, Dmytro et al. (2014) Phenyl-1-Pyridin-2yl-ethanone-based iron chelators increase I?B-? expression, modulate CDK2 and CDK9 activities, and inhibit HIV-1 transcription. Antimicrob Agents Chemother 58:6558-71
Castro, Oswaldo; Nouraie, Mehdi; Oneal, Patricia (2014) Hydroxycarbamide treatment in sickle cell disease: estimates of possible leukaemia risk and of hospitalization survival benefit. Br J Haematol 167:687-91
Chasnyk, Vyacheslav; Fedorova, Elena; Egorov, Andrey et al. (2014) A130: Is the CCR5-delta32 Mutation Protective Against Systemic-Onset Juvenile Idiopathic Arthritis? Arthritis Rheumatol 66 Suppl 3:S171
Ilinykh, Philipp A; Tigabu, Bersabeh; Ivanov, Andrey et al. (2014) Role of protein phosphatase 1 in dephosphorylation of Ebola virus VP30 protein and its targeting for the inhibition of viral transcription. J Biol Chem 289:22723-38
Nekhai, Sergei; Hynes, Alla; Ammosova, Tatiana et al. (2014) A128: hierarchical clustering methodology for exploration of proteomic profile in tears: seeking for markers of uveitis associated with juvenile idiopathic arthritis. Arthritis Rheumatol 66 Suppl 11:S168
Ashenafi, Meseret; Ammosova, Tatiana; Nekhai, Sergei et al. (2014) Purification and characterization of aminoglycoside phosphotransferase APH(6)-Id, a streptomycin-inactivating enzyme. Mol Cell Biochem 387:207-16